Alejo, E.; Agulló, C.; Puertas, B.; Eiros, R.; Rey-Búa, B.; Barnés, C.; Rodríguez-González, M.; López-Corral, L.; Santos-Briz, Á.; Escalante, F.;
et al. Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience. Cancers 2025, 17, 1440.
https://doi.org/10.3390/cancers17091440
AMA Style
Alejo E, Agulló C, Puertas B, Eiros R, Rey-Búa B, Barnés C, Rodríguez-González M, López-Corral L, Santos-Briz Á, Escalante F,
et al. Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience. Cancers. 2025; 17(9):1440.
https://doi.org/10.3390/cancers17091440
Chicago/Turabian Style
Alejo, Elena, Cristina Agulló, Borja Puertas, Rocío Eiros, Beatriz Rey-Búa, Carmen Barnés, Marta Rodríguez-González, Lucía López-Corral, Ángel Santos-Briz, Fernando Escalante,
and et al. 2025. "Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience" Cancers 17, no. 9: 1440.
https://doi.org/10.3390/cancers17091440
APA Style
Alejo, E., Agulló, C., Puertas, B., Eiros, R., Rey-Búa, B., Barnés, C., Rodríguez-González, M., López-Corral, L., Santos-Briz, Á., Escalante, F., Pérez-García, M.-L., Jiménez-Cabrera, S., Gutiérrez, N. C., Puig, N., Mateos, M.-V., & González-Calle, V.
(2025). Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience. Cancers, 17(9), 1440.
https://doi.org/10.3390/cancers17091440